Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 1
2010 5
2011 1
2014 1
2015 1
2016 1
2017 2
2018 1
2019 3
2020 1
2021 1
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Results by year
Filters applied: . Clear all
Page 1
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer.
Patil NS, Nabet BY, Müller S, Koeppen H, Zou W, Giltnane J, Au-Yeung A, Srivats S, Cheng JH, Takahashi C, de Almeida PE, Chitre AS, Grogan JL, Rangell L, Jayakar S, Peterson M, Hsia AW, O'Gorman WE, Ballinger M, Banchereau R, Shames DS. Patil NS, et al. Among authors: o gorman we. Cancer Cell. 2022 Mar 14;40(3):289-300.e4. doi: 10.1016/j.ccell.2022.02.002. Epub 2022 Feb 24. Cancer Cell. 2022. PMID: 35216676
Peripheral T cell expansion predicts tumour infiltration and clinical response.
Wu TD, Madireddi S, de Almeida PE, Banchereau R, Chen YJ, Chitre AS, Chiang EY, Iftikhar H, O'Gorman WE, Au-Yeung A, Takahashi C, Goldstein LD, Poon C, Keerthivasan S, de Almeida Nagata DE, Du X, Lee HM, Banta KL, Mariathasan S, Das Thakur M, Huseni MA, Ballinger M, Estay I, Caplazi P, Modrusan Z, Delamarre L, Mellman I, Bourgon R, Grogan JL. Wu TD, et al. Among authors: o gorman we. Nature. 2020 Mar;579(7798):274-278. doi: 10.1038/s41586-020-2056-8. Epub 2020 Feb 26. Nature. 2020. PMID: 32103181
Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses.
Banta KL, Xu X, Chitre AS, Au-Yeung A, Takahashi C, O'Gorman WE, Wu TD, Mittman S, Cubas R, Comps-Agrar L, Fulzele A, Bennett EJ, Grogan JL, Hui E, Chiang EY, Mellman I. Banta KL, et al. Among authors: o gorman we. Immunity. 2022 Mar 8;55(3):512-526.e9. doi: 10.1016/j.immuni.2022.02.005. Immunity. 2022. PMID: 35263569 Free PMC article.
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade.
Banchereau R, Chitre AS, Scherl A, Wu TD, Patil NS, de Almeida P, Kadel Iii EE, Madireddi S, Au-Yeung A, Takahashi C, Chen YJ, Modrusan Z, McBride J, Nersesian R, El-Gabry EA, Robida MD, Hung JC, Kowanetz M, Zou W, McCleland M, Caplazi P, Eshgi ST, Koeppen H, Hegde PS, Mellman I, Mathews WR, Powles T, Mariathasan S, Grogan J, O'Gorman WE. Banchereau R, et al. Among authors: o gorman we. J Immunother Cancer. 2021 Apr;9(4):e002231. doi: 10.1136/jitc-2020-002231. J Immunother Cancer. 2021. PMID: 33827905 Free PMC article.
Quantitative Comparison of Conventional and t-SNE-guided Gating Analyses.
Toghi Eshghi S, Au-Yeung A, Takahashi C, Bolen CR, Nyachienga MN, Lear SP, Green C, Mathews WR, O'Gorman WE. Toghi Eshghi S, et al. Among authors: o gorman we. Front Immunol. 2019 Jun 5;10:1194. doi: 10.3389/fimmu.2019.01194. eCollection 2019. Front Immunol. 2019. PMID: 31231371 Free PMC article.
Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
Fehlings M, Jhunjhunwala S, Kowanetz M, O'Gorman WE, Hegde PS, Sumatoh H, Lee BH, Nardin A, Becht E, Flynn S, Ballinger M, Newell EW, Yadav M. Fehlings M, et al. Among authors: o gorman we. J Immunother Cancer. 2019 Sep 12;7(1):249. doi: 10.1186/s40425-019-0695-9. J Immunother Cancer. 2019. PMID: 31511069 Free PMC article. Clinical Trial.
Duration of antigen receptor signaling determines T-cell tolerance or activation.
Katzman SD, O'Gorman WE, Villarino AV, Gallo E, Friedman RS, Krummel MF, Nolan GP, Abbas AK. Katzman SD, et al. Among authors: o gorman we. Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):18085-90. doi: 10.1073/pnas.1010560107. Epub 2010 Oct 4. Proc Natl Acad Sci U S A. 2010. PMID: 20921406 Free PMC article.
21 results